Related Experiment Videos
Sufentanil pharmacokinetics in pediatric cardiovascular patients
W J Greeley1, N P de Bruijn, D P Davis
1Department of Anesthesiology, Duke University Medical Center, Durham, NC 27710.
Insights
Sufentanil pharmacokinetics in pediatric cardiovascular surgery patients show significant age-related differences. Neonates exhibit lower clearance, larger distribution volume, and longer half-life, requiring higher drug concentrations for anesthesia.
Area of Science:
- Pharmacology
- Pediatric Anesthesiology
- Cardiovascular Surgery
Background:
- Sufentanil is a potent opioid analgesic used in pediatric anesthesia.
- Understanding its pharmacokinetics is crucial for safe and effective use in pediatric patients, especially those undergoing complex procedures.
- Age-specific pharmacokinetic data are essential for optimizing drug dosing in diverse pediatric populations.
Purpose of the Study:
- To investigate the pharmacokinetics of sufentanil in pediatric patients across different age groups undergoing cardiovascular surgery.
- To identify age-related differences in sufentanil clearance, volume of distribution, and elimination half-life.
- To correlate pharmacokinetic parameters with pharmacodynamic responses, specifically the concentration required for anesthetic supplementation.
Main Methods:
- A pharmacokinetic study involving 28 pediatric patients (neonates, infants, children, adolescents) undergoing cardiovascular procedures.
- Intravenous bolus administration of sufentanil (10-15 micrograms/kg).
- Plasma concentrations of sufentanil were measured for up to 20 hours; data analyzed using a tri-exponential equation.
Main Results:
- Significantly lower clearance rate (Cl) in neonates (6.7 ml.kg-1.min-1) compared to infants, children, and adolescents.
- Significantly greater volume of distribution at steady state (Vdss) in neonates (4.15 L/kg) versus children and adolescents.
- Significantly longer elimination half-life (T1/2 beta) in neonates (783 min) compared to other age groups; higher sufentanil concentrations needed for anesthesia in neonates.
Conclusions:
- Significant age-related variations in sufentanil pharmacokinetics and pharmacodynamics exist in pediatric patients with cardiovascular disease undergoing surgery.
- Neonates demonstrate distinct pharmacokinetic profiles, necessitating careful consideration for dosing and monitoring.
- These findings underscore the importance of age-specific dosing strategies for sufentanil in pediatric surgical populations.
Abstract:
The pharmacokinetics of sufentanil were studied in 28 pediatric patients undergoing cardiovascular procedures. Patients were divided into four groups on the basis of age: neonates (0-1 month, n = 9), infants (1-24 months, n = 7), children (2-12 yr, n = 7), and adolescents (12-18 yr, n = 5). Sufentanil 10-15 micrograms/kg, was administered by IV bolus and plasma concentrations measured for up to 20 hr. A tri-exponential equation best described the time-concentration data in all patients. Clearance rate (Cl) was 6.7 +/- 6.1 ml.kg-1.min-1 (+/- SD) in neonates, which was significantly lower than the values of 18.1 +/- 2.7, 16.9 +/- 3.2, and 13.1 +/- 3.6 ml.kg-1 min-1 observed in infants, children, and adolescents, respectively. The volume of distribution at steady state (Vdss) was 4.15 +/- 1.0 L/kg in neonates, significantly greater than the values of 2.73 +/- 0.5 and 2.75 +/- 0.5 L/kg observed in children and adolescents, respectively. The elimination half-life (T1/2 beta) was 783 +/- 346 min in neonates, significantly longer than the values of 214 +/- 41, 140 +/- 30, and 209 +/- 23 min observed in infants, children, and adolescents, respectively. The plasma concentration of sufentanil at the time of additional anesthetic supplementation to suppress hemodynamic responses to surgical stimulation was 2.51 ng/ml in neonates, significantly higher than the levels of 1.58, 1.53, and 1.56 ng/ml observed in infants, children, and adolescents, respectively. The authors conclude that age-related differences in pharmacokinetic and pharmacodynamic properties of sufentanil are evident in pediatric patients with major cardiovascular disease who are undergoing cardiovascular surgery.